Account
Inquiry
Tirzepatide 20mg is a pharmaceutical-grade peptide compound with CAS number 2023788-19-2. This white powder formulation contains 99.9% pure tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
As a research compound, tirzepatide 20mg has demonstrated significant efficacy in clinical studies for both glucose control and weight management. The molecular formula of this peptide is C225H348N48O68, with a molecular weight of 4813. The lysine side chain in its sequence features PEG modification, enhancing water solubility.
Clinical trials have shown tirzepatide 20mg produces superior results compared to selective GLP-1 receptor agonists. In the SURMOUNT-1 trial, participants achieved average weight reductions of 15-20.9% over 72 weeks depending on dosage. This makes tirzepatide 20mg particularly interesting for metabolic disorder research.
The peptide works by mimicking natural GIP at the GIP receptor while also activating GLP-1 receptors. This dual mechanism provides enhanced effects on blood sugar regulation and satiety signals compared to single-pathway agonists.
For research purposes, tirzepatide 20mg is supplied as a lyophilized powder in sterile vials. Each vial contains precisely 20mg of active peptide compound. The product is packaged with 10 vials per box, suitable for laboratory use.
As with all research compounds, proper storage is essential for maintaining tirzepatide 20mg stability. The peptide should be kept in a cool, dry environment protected from light. Avoid repeated freeze-thaw cycles and minimize exposure to air when handling.
This product is intended for research use only by qualified professionals. Tirzepatide 20mg is not for human consumption or diagnostic use. Researchers should follow all applicable regulations and safety protocols when handling this compound.
